ReproCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies.
Launch date
Employees
Market cap
AUD136m
Enterprise valuation
AUD67m (Public information from Sep 2024)
Share price
JPY129 4978.T
Yokohama Kanagawa Prefecture (HQ)
Financials
Estimates*
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.2b | 1.3b | 2.2b | 3.0b | 2.4b | 374m | 412m |
| % growth | - | 7 % | 74 % | 32 % | (18 %) | (85 %) | 10 % |
| EBITDA | (838m) | (766m) | (438m) | (116m) | 78.0m | (300m) | (140m) |
| % EBITDA margin | (70 %) | (60 %) | (20 %) | (4 %) | 3 % | (80 %) | (34 %) |
| Profit | (1.0b) | (813m) | (575m) | (305m) | (31.4m) | (170m) | (20.0m) |
| % profit margin | (85 %) | (63 %) | (26 %) | (10 %) | (1 %) | (45 %) | (5 %) |
| EV / revenue | 17.6x | 19.5x | 6.3x | 4.8x | 3.1x | 17.0x | 15.7x |
| EV / EBITDA | -25.2x | -32.7x | -31.9x | -121.8x | 95.5x | -21.2x | -46.1x |
| R&D budget | 455m | 662m | 535m | 502m | 385m | - | - |
| R&D % of revenue | 38 % | 51 % | 24 % | 17 % | 16 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Early VC | ||
$2.0m | Early VC | ||
| N/A | N/A | IPO | |
* | N/A | Grant | |
| Total Funding | AUD3.1m | ||
Related Content
Recent News about ReproCELL
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
